Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid Abushahba

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical & Developmental Immunology|December 23, 2011
Interferon lambda: a new sword in cancer immunotherapyAhmed Lasfar, Walid Abushahba, Murugabaskar Balan, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2010
Antitumor activity of type I and type III interferons in BNL hepatoma modelWalid Abushahba, Murugabaskar Balan, Ismael Castaneda, et al.
Plos One|October 19, 2012
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanomaWalid Abushahba, Oyenike O Olabisi, Byeong-Seon Jeong, et al.
Oncotarget|July 1, 2016
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growthAhmed Lasfar, Andrew de laTorre, Walid Abushahba, et al.
Cancer Research|April 19, 2006
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanomaAhmed Lasfar, Anita Lewis-Antes, Sergey V Smirnov, et al.
Cancer Letters|March 25, 2014
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasionRajeev K Boregowda, Oyenike O Olabisi, Walid Abushahba, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical & Developmental Immunology|December 23, 2011
Interferon lambda: a new sword in cancer immunotherapyAhmed Lasfar, Walid Abushahba, Murugabaskar Balan, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2010
Antitumor activity of type I and type III interferons in BNL hepatoma modelWalid Abushahba, Murugabaskar Balan, Ismael Castaneda, et al.
Plos One|October 19, 2012
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanomaWalid Abushahba, Oyenike O Olabisi, Byeong-Seon Jeong, et al.
Oncotarget|July 1, 2016
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growthAhmed Lasfar, Andrew de laTorre, Walid Abushahba, et al.
Cancer Research|April 19, 2006
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanomaAhmed Lasfar, Anita Lewis-Antes, Sergey V Smirnov, et al.
Cancer Letters|March 25, 2014
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasionRajeev K Boregowda, Oyenike O Olabisi, Walid Abushahba, et al.
Pageof 1